Mutations in DNMT3A, TET2, IDH1, and IDH2 each occur in 7–23% of AML cases [12], and are also found in clonal hematopoiesis of indeterminate potential (CHIP), a condition prevalent in elderly people and patients in remission after treatment for AML [13]. This evidence concerns the gene IDH2 and acute myeloid leukemia.